Jacobs Christopher R, Scali Salvatore T, Khan Tabassum, Cadavid Felipe, Staton Kyle M, Feezor Robert J, Back Martin R, Upchurch Gilbert R, Huber Thomas S
Division of Vascular Surgery and Endovascular Therapy, University of Florida, Gainesville, Fla.
Division of Vascular Surgery and Endovascular Therapy, University of Florida, Gainesville, Fla.
J Vasc Surg. 2022 Jan;75(1):144-152.e1. doi: 10.1016/j.jvs.2021.07.121. Epub 2021 Jul 24.
Although endovascular aneurysm repair (EVAR) reintervention is common, conversion to open repair (EVAR-c) occurs less frequently but can be associated with significant technical complexity and perioperative risk. There is a paucity of data highlighting the evolution of periprocedural results surrounding EVAR-c and change in practice patterns, especially for referral centers that increasingly manage EVAR failures. The purpose of this analysis was to perform a temporal analysis of our EVAR-c experience and describe changes in patient selection, operative details, and outcomes.
A retrospective single-center review of all open abdominal aortic aneurysm repairs was performed (2002-2019), and EVAR-c procedures were subsequently analyzed. EVAR-c patients (n = 184) were categorized into two different eras (2002-2009, n = 21; 2010-2019, n = 163) for comparison. Logistic regression and Cox proportional hazards modeling were used for risk-adjusted comparisons.
A significant increase in EVAR-c as an indication for any type of open aneurysm repair was detected (9% to 27%; P < .001). Among EVAR-c patients, no change in age or individual comorbidities was evident (mean age, 71 ± 9 years); however, the proportion of female patients (P = .01) and American Society of Anesthesiologists classification >3 declined (P = .05). There was no difference in prevalence (50% vs 43%; P = .6) or number (median, 1.5 [interquartile range (IQR), 0-5]) of preadmission EVAR reinterventions; however, time to reintervention decreased (median, 23 [IQR, 6-34] months vs 0 [IQR, 0-22] months; P = .005). In contrast, time to EVAR-c significantly increased (median, 16 [IQR, 9-39] months vs 48 [IQR, 20-83] months; P = .008). No difference in frequency of nonelective presentation (mean, 52%; P = .9] or indication was identified, but a trend toward increasing mycotic EVAR-c was observed (5% vs 15%; P = .09). Use of retroperitoneal exposure (14% vs 77%; P < .0001), suprarenal cross-clamp application (6286%; P = .04), and visceral-ischemia time (median, 0 [IQR, 0-11] minutes vs 5 [IQR, 0-20] minutes; P = .05) all increased. In contrast, estimated blood loss (P trend = .03) and procedure time (P = .008) decreased. The unadjusted elective 30-day mortality rate improved but did not reach statistical significance (elective, 10% vs 5%; P = .5) with no change for non-elective operations (18% vs 16%; P = .9). However, a significantly decreased risk of complications was evident (odds ratio, 0.88; 95% confidence interval, .8-.9; P = .01). One- and 3-year survival was similar over time.
EVAR-c is now a common indication for open abdominal aortic aneurysm repair. Patients frequently present nonelectively and at increasingly later intervals after their index EVAR. Despite increasing technical complexity, decreased complication risk and comparable survival can be anticipated when patients are managed at a high-volume aortic referral center.
尽管血管内动脉瘤修复术(EVAR)再干预很常见,但转为开放修复术(EVAR-c)的情况较少见,但可能伴有显著的技术复杂性和围手术期风险。目前缺乏数据突出EVAR-c围手术期结果的演变以及实践模式的变化,特别是对于越来越多地处理EVAR失败病例的转诊中心。本分析的目的是对我们的EVAR-c经验进行时间分析,并描述患者选择、手术细节和结果的变化。
对所有开放性腹主动脉瘤修复术进行回顾性单中心研究(2002 - 2019年),随后分析EVAR-c手术。将EVAR-c患者(n = 184)分为两个不同时期(2002 - 2009年,n = 21;2010 - 2019年,n = 163)进行比较。采用逻辑回归和Cox比例风险模型进行风险调整比较。
检测到EVAR-c作为任何类型开放性动脉瘤修复术指征的显著增加(9%至27%;P <.001)。在EVAR-c患者中,年龄或个体合并症无明显变化(平均年龄,71±9岁);然而,女性患者比例(P =.01)和美国麻醉医师协会分级>3的比例下降(P =.05)。入院前EVAR再干预的患病率(50%对43%;P =.6)或次数(中位数,1.5[四分位间距(IQR),0 - 5])无差异;然而,再干预时间缩短(中位数,23[IQR,6 - 34]个月对0[IQR,0 - 22]个月;P =.005)。相比之下,至EVAR-c的时间显著增加(中位数,16[IQR,9 - 39]个月对48[IQR,20 - 83]个月;P =.008)。非择期就诊频率(平均,52%;P =.9)或指征无差异,但观察到感染性EVAR-c有增加趋势(5%对15%;P =.09)。腹膜后暴露的使用(14%对77%;P <.0001)、肾上腹主动脉阻断的应用(62%对86%;P =.04)和内脏缺血时间(中位数,0[IQR,0 - 11]分钟对5[IQR,0 - 20]分钟;P =.05)均增加。相比之下,估计失血量(P趋势 =.03)和手术时间(P =.008)减少。未调整的择期30天死亡率有所改善但未达到统计学意义(择期,10%对5%;P =.5),非择期手术无变化(18%对16%;P =.9)。然而,并发症风险显著降低(比值比,0.88;95%置信区间,.8 -.9;P =.01)。1年和3年生存率随时间相似。
EVAR-c现在是开放性腹主动脉瘤修复术的常见指征。患者常非择期就诊,且在初次EVAR后间隔越来越长的时间就诊。尽管技术复杂性增加,但在大容量主动脉转诊中心对患者进行管理时,可预期并发症风险降低且生存率相当。